Will PP405 work if even dutasteride / fin failed to halt hair loss?
    Finasteride/Dutasteride 3/29/2026

    From the encyclopedia
    Dutasteride →

    Heavy duty finasteride that comes with higher risks

    PP405 →

    mitochondrial pyruvate carrier (MPC) inhibitor by Pelage in early trials

    At a glance
    In this question or advice post, the primary subjects mentioned are
    💊 Dutasteride (oral) 0.5mg daily 1 year
    the tone is 😞 negative with no growth results.

    Other terms

    The conversation discusses the ineffectiveness of dutasteride in halting hair loss for the user and explores the potential of PP405, which works through a different mechanism. Suggestions include considering a biopsy to determine the cause of hair loss and exploring other treatments like RU58841.
    View this post in the Community →

    Similar Community Posts Join

    5 / 5 results

    Related Research

    6 / 6 results
      New Therapeutics in the Management of Androgenetic Alopecia

      research Nouvelles thérapeutiques dans la prise en charge de l’alopécie androgénétique

      March 2025 in “HAL (Le Centre pour la Communication Scientifique Directe)”
      This thesis investigates the underlying mechanisms and treatment options for androgenetic alopecia, highlighting the molecular roles of androgens and genetic predispositions, and evaluates current and emerging therapies, such as PROTACs and Janus Kinase inhibitors, to enhance patient management.
      Recent Advances in Drug Development for Hair Loss

      research Recent Advances in Drug Development for Hair Loss

      April 2025 in “International Journal of Molecular Sciences”
      This review highlights the limitations of existing hair loss treatments like minoxidil and finasteride and suggests that future therapies may benefit from focusing on antibody and cell-based treatments, which offer targeted and potentially transformative options for managing hair loss disorders.
      PP405 in Alopecia: An Emerging Molecule Worth Investigating

      research PP405 in Alopecia: An Emerging Molecule worth Investigating

      January 2026 in “Journal of Community Medicine and Health Solutions”
      In this study, the novel topical agent PP405 showed favorable tolerability and increased hair density by over 20% in men with advanced androgenetic alopecia after eight weeks, suggesting a promising potential treatment pending further trials.
      Diagnostic Comparison: SH-1 Molecule vs PP405 — Safety Profiles in Hair Science

      research Diagnostic Comparison: SH‑1 Molecule vs PP405 — Safety Profiles in Hair Science

      June 2026 in “HAL (Le Centre pour la Communication Scientifique Directe)”
      This infographic compares the safety profiles of SH‑1, a cosmetic ingredient, which showed no systemic absorption, and PP405, an investigational drug with dose-dependent systemic uptake and potential threshold breaches, highlighting differences in safety between cosmetic and investigational substances according to this report.
      Review of the 2024 American Academy of Dermatology Annual Meeting

      research Review of the 2024 American Academy of Dermatology (AAD) Annual Meeting

      April 2024
      This report describes the 2024 American Academy of Dermatology Annual Meeting in San Diego, notable for attracting nearly 20,000 attendees with 339 sessions covering a wide range of dermatological topics, making it potentially the largest dermatology meeting by attendance.